Endocrine最新文献

{"title":"Proportion of depression in diabetes patients: A Cross-Sectional study using HAM-D scale.","authors":"Muhammad Unais, Muskan Malviya","doi":"10.1007/s12020-025-04412-7","DOIUrl":"https://doi.org/10.1007/s12020-025-04412-7","url":null,"abstract":"<p><strong>Background: </strong>Depression is a common but often underrecognized comorbidity in individuals with diabetes mellitus. Identifying its prevalence can help in early intervention and better management.</p><p><strong>Objective: </strong>To estimate the proportion of depression in patients with diabetes mellitus using the Hamilton Depression Rating Scale (HAM-D) and to evaluate associations with gender, age, diabetes duration, and comorbid conditions.</p><p><strong>Methods: </strong>This descriptive cross-sectional study was conducted among 89 diabetic patients attending outpatient services at a tertiary care hospital. Data was collected via structured interviews using the HAM-D [1] questionnaire. A HAM-D score ≥ 8 was considered indicative of depression. Data analysis was conducted using descriptive statistics and subgroup analysis based on gender, age groups, and other variables.</p><p><strong>Results: </strong>Among 89 patients, 26 (29.2%) were found to have depression. The prevalence was higher in females (36.8%) compared to males (23.5%). Depression was more frequent in older age groups, particularly among patients aged 60-74 years. [Pie chart and bar graphs to be inserted.] CONCLUSION: A significant proportion of diabetic patients exhibit depressive symptoms, particularly older individuals and females. Routine screening using tools like HAM-D can aid in early identification and intervention.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life and treatment burden of children receiving daily growth hormone treatment in Greece.","authors":"Athanasios Christoforidis, Fotini-Eleni Karachaliou, Assimina Galli-Tsinopoulou, Dionisios Chrysis, Christina Kanaka-Gantenbein, Evangelia Baxevanidi, Ioannis Skiadas, Oresteia Zisimopoulou, Apostolia Poimenidou, Dimitrios Tsilakis, Elpis-Athina Vlachopapadopoulou","doi":"10.1007/s12020-025-04269-w","DOIUrl":"10.1007/s12020-025-04269-w","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the paediatric growth hormone deficiency burden in Greek patients and their caregivers regarding the health-related quality of life (HRQoL), impact of recombinant human growth hormone (rhGH) treatment, and disease management.</p><p><strong>Method: </strong>In this cross-sectional study, Quality of Life in Short Stature Youth (QoLISSY) and Life Interference for GHD (LIQ-GHD) questionnaires were administered to both patients with pGHD aged 4-17 years receiving rhGH for minimum 12 months and their caregivers.</p><p><strong>Results: </strong>This study included 250 patients and their caregivers. The mean ( ± SD) total QoLISSY scores were 80.93 (±14.63) and 76.32 (±17.68) reported by patients and caregivers, respectively. Patients ≥ 8 years scored higher in total and emotional domains compared to caregivers, whereas the treatment domain was lower in patients > 12 years versus caregivers. Ease of injection schedule, life interference, and willingness to continue LIQ-GHD domains mainly comprised treatment burden, with mean (±SD) scores of 19.88 (±22.02), 19.36 (±18.39) and 19.25 (±19.60), respectively. Treatment adherence in the overall population was satisfactory. Patients ≥ 8 years missed more injections than younger individuals.</p><p><strong>Conclusion: </strong>A good HRQoL and a mild treatment burden were reported by Greek patients receiving daily rhGH and their caregivers; however, variability was observed within children's and caregivers' groups. Considering the decreased compliance during adolescence, emphasis should be given to consultations with patients and caregivers to identify issues and address them accordingly. Finally, there is a need to consider alternative treatment regimens which could improve adherence.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"858-868"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-specific factors, patient preference, and nodule size as implications in the initial surgery of high risk indeterminate thyroid nodules.","authors":"Lorenzo Scappaticcio, Nicole Di Martino, Pamela Ferrazzano, Stefano Lucà, Eduardo Clery, Miriam Longo, Vanda Amoresano Paglionico, Giovanni Cozzolino, Maria Ida Maiorino, Giovanni Docimo, Pierpaolo Trimboli, Renato Franco, Katherine Esposito, Giuseppe Bellastella","doi":"10.1007/s12020-025-04289-6","DOIUrl":"10.1007/s12020-025-04289-6","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the frequency of total thyroidectomy (TT) for thyroid nodules cytologically classified as high-risk indeterminate (TIR3B) and to explore the impact of patient specific factors (PSFs) (some clinical variables) associated with TT for follicular thyroid carcinoma (FTC). Moreover, we aim to investigate the nodule size as a factor influencing the risk of malignancy (ROM) and the risk of aggressiveness of FTC.</p><p><strong>Methods: </strong>We retrieved consecutive FTC cases, and an equal number of follicular adenoma (FA) from adult patients with TIR3B thyroid nodules, which were operated in our Academic referral center between March 1, 2018, and December 31, 2024.</p><p><strong>Results: </strong>We reviewed 112 TIR3B thyroid nodules, histologically subdivided into 56 FTC cases and 56 FA cases. TT was performed in 83% of cases. PSFs were present in 47.4% of patients undergoing hemithyroidectomy (HT) and in 61.3% of patients undergoing TT. No statistical significance was found for PSFs as predictors of TT. For the 30 mm ≤ dmax <40 mm size category we found an odds ratio (OR) of 2.0 [1.101; 3.551] (p-value 0.022) for risk of FTC. We found the existence of a positive relationship between dimensions of FTC and its aggressiveness.</p><p><strong>Conclusion: </strong>TT was largely performed as initial surgery for TIR3B thyroid nodules. PSFs and patient preferences should be explored when planning the initial surgical management of a nodule with TIR3B cytology. Large nodule size (30 ≤ dmax < 40) can be integrated into decision making for patients with a cytology of TIR3B, since it increases the risk of FTC. Larger FTC seems to be more aggressive.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"793-799"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144163190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mild chronic post-natal pain induces endocrine and metabolic alterations associated to enlargement in pituitary glands size in adult CD-1 male mice.","authors":"Teresa Dipol, Andrea Fortuna, Ornella Morsilli, Valentina Zecca, Taljinder Singh, Gianmauro Palombelli, Fabrizio Mattei, Vittoria Favero, Niccolò Candelise, Zaira Maroccia, Alberto Loizzo, Roberto Rimondini, Gabriele Campana, Natalia Simona Pellegata, Stefano Loizzo, Rossella Canese, Iacopo Chiodini","doi":"10.1007/s12020-025-04297-6","DOIUrl":"10.1007/s12020-025-04297-6","url":null,"abstract":"<p><strong>Background: </strong>Human adverse childhood experiences (ACEs) are associated with various types of mental and physical pathological outcomes in adulthood. Among them, they may present the enlargement of the pituitary gland and have been suggested to be a risk factor for the development of Cushing syndrome. Previously, we showed on outbred CD-1 male mice that chronic pain induced during the weaning time by pharmacological experimental design procedures caused endocrine and metabolic alterations in adulthood, suggestive of human mild hypercortisolism. Specifically, we observed an increase in pituitary glands weight and in adrenocorticotropic hormone (ACTH) expression, associated with the lack of the negative feedback mechanisms exerted by corticosterone that controls proopiomelanocortin- derived ACTH secretion.</p><p><strong>Methods: </strong>Here, to better understand the phenotype of mice subjected to early-life pain (ELP), their pituitary glands were examined. Mice tissues and plasma hormones measurements were conducted by ELISA assays. Analysis of brain and pituitary gland was performed using anatomic and diffusion-weighted magnetic resonance imaging. Hematoxylin and eosin-stained sections of pituitary glands were also examined.</p><p><strong>Results: </strong>Mice subjected to ELP showed an increase in total body weight, in pituitary ACTH expression and in plasmatic corticosterone levels. Imaging of the pituitary glands revealed a significant increment of their volume without apparent pathological alterations.</p><p><strong>Conclusion: </strong>The findings of this study may support the role of ELP as a risk factor for ACTH-dependent hypercortisolism in adulthood associated with an enlarged pituitary gland.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"698-703"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1RA and the possible skin aging.","authors":"Ioanna A Paschou, Evangelia Sali, Stavroula A Paschou, Konstantinos I Tsamis, Melpomeni Peppa, Theodora Psaltopoulou, Electra Nicolaidou, Alexander J Stratigos","doi":"10.1007/s12020-025-04293-w","DOIUrl":"10.1007/s12020-025-04293-w","url":null,"abstract":"<p><p>\"Ozempic face\" and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic inflammation and possibly promote skin health. The rapid weight loss observed with GLP-1RA has been implicated in facial aging. However, recent evidence suggests further pathophysiological mechanisms for this side effect. The aim of this article is to review the literature and present available data on the possible mechanisms of GLP-1RA on skin aging. Indeed, GLP-1RA may affect other types of skin cells, which may accelerate the process of skin aging itself. More specifically, GLP-1RA can act on adipose-derived stem cells (ADSC) and fibroblasts, that present GLP-1R on their surface. Stimulation of the receptor reduces the ability of ADSC to produce protective cytokines. The absence of those cytokines promotes the production of reactive oxygen species (ROS) and causes oxidative damage on fibroblasts. GLP-1RA also reduce the glucose intake of the ADSC, leading to reduced production of ATP and apoptosis. Finally, the stimulation of GLP-1R on ADSCs reduces indirectly the production of estrogens from dermal white adipose tissues (DWAT), which reduces stimulation of fibroblasts to produce collagen. GLP-1RA can also affect the process of skin aging through interaction with advanced glycation end products (AGEs) and RAGE (receptors of AGEs) activation. In conclusion, many patients receiving GLP-1RA suffer from \"Ozempic face\" and facial aging. It seems that this complication is not exclusively related to decreased facial fat, but there are more aging mechanisms that have to be elucidated.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"680-685"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for postpartum prediabetes and type 2 diabetes in women with gestational diabetes: insights from the edugest study in Argentina.","authors":"J F Elgart, S Salzberg, E Mendez, P Pereyra, N I Gimenez, S Paco Leaños, L A Otiñano Merlo, M A Barrios, I Oliveros, A M Tetta Mirabal, E Sosa, S Rueda, M I Argerich, R A David, C V Farias, S Gorban de Lapertosa","doi":"10.1007/s12020-025-04313-9","DOIUrl":"10.1007/s12020-025-04313-9","url":null,"abstract":"<p><strong>Aim: </strong>To describe postpartum glycemic status in a cohort of women with Gestational diabetes (GD) from the EDUGEST (Education in women with GD) study, and to determine factors associated with a diagnosis of prediabetes or T2D.</p><p><strong>Methods: </strong>This observational, analytical study analyzed records of pregnant women with GD recruited in the framework of the EDUGEST study. Data from QUALIDAB-GEST were analyzed for patients who completed postpartum glycemic assessment at six weeks. Information included concurrent cardiovascular risk factors, obstetric history in previous pregnancies, clinical and metabolic indicators, treatments, and postpartum screening results. Descriptive analyses were performed using means ± standard deviation (SD), medians with interquartile ranges [IQR], or proportions, as appropriate. Differences were tested using parametric and non-parametric tests. Regression models assessed factors associated with prediabetes or T2D development postpartum.</p><p><strong>Results: </strong>The analysis included 573 patients (median age: 31 [26-36] years; median gestational age at the first specialty visit after GD diagnosis: 28 [26-32] weeks; BMI: 31.2 [26.7-34.9]). Postpartum screening showed 76.3% normal results, 19.5% prediabetes, and 4.2% T2D. T2D was significantly associated with insulin use during pregnancy (OR: 4.20) and family history of diabetes (OR: 3.21), while prediabetes was associated with hypertension (OR: 2.39), insulin use during pregnancy (OR: 1.62), BMI al the first specialty visit (OR: 1.05), and fructosamine levels (OR: 1.01).</p><p><strong>Conclusion: </strong>This study identified locally relevant parameters associated with postpartum prediabetes and T2D in women with GD, highlighting the importance of early identification of high-risk patients and the role of postpartum glycemic assessment for timely diagnosis.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"765-771"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Height benefits after GnRHa treatment in girls aged over 6 years with central precocious puberty: a meta-analysis.","authors":"Ming Chen, Jie-Yu Sun, Xing Ji, Ming-Ming Ni","doi":"10.1007/s12020-025-04332-6","DOIUrl":"10.1007/s12020-025-04332-6","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this meta-analysis was to evaluate the impact of gonadotropin-releasing hormone analog (GnRHa) treatment on height outcomes in girls aged over 6 years with central precocious puberty (CPP).</p><p><strong>Methods: </strong>A systematic search was performed across PubMed, Cochrane Library, Web of Science, MEDLINE, EMBASE, CNKI, and Wan Fang databases to identify eligible studies. The meta-analysis protocol was registered at PROSPERO, and the quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects meta-analysis was used to synthesize data on height gain, final adult height (FAH), FAH standard deviation score (SDS), bone age, and the difference between FAH and target height (TH).</p><p><strong>Results: </strong>Fifteen studies including 1270 girls were identified. The results indicated that GnRHa therapy significantly improves height outcomes in girls with CPP aged over 6 years. By effectively delaying pubertal progression and bone age maturation, GnRHa treatment enables these girls to achieve a greater FAH and potentially surpass their TH. Meta-analysis showed that the GnRHa treatment group demonstrated significantly greater height gain (WMD = 2.52, 95% CI [1.66, 3.37]), FAH (WMD = (WMD = 3.18, 95% CI [1.49, 4.87]), and FAH minus TH (WMD = 0.61, 95% CI [0.42, 0.79]) compared to the control group. Additionally, bone age (WMD = -1.02, 95%CI [-1.99, -0.06]) was significantly lower than the control group. However, FAH SDS showed no significant difference between the groups (WMD = 0.09, 95%CI [-0.40, 0.58]).</p><p><strong>Conclusions: </strong>GnRHa treatment demonstrates substantial benefits in promoting height outcomes in girls over 6 years old with CPP. This meta-analysis contributes to the growing body of evidence supporting the efficacy of GnRHa in managing CPP and underscores the importance of early intervention to maximize height potential in affected individuals.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"686-697"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increase in visceral adipose tissue and altered metabolic profile in transgender men but not in transgender women one year after starting gender-affirming hormonal therapy.","authors":"Clément Larose, Caroline Samhani, Pierre Consolandi, Eva Feigerlova","doi":"10.1007/s12020-025-04310-y","DOIUrl":"10.1007/s12020-025-04310-y","url":null,"abstract":"<p><strong>Context: </strong>Increase in body fat and dyslipidemia have been reported in persons receiving gender-affirming hormone therapy (GAHT). However, little is known whether these changes are associated with a pro-inflammatory state.</p><p><strong>Objective: </strong>To study the relationship between changes in body composition, cardiometabolic parameters and systemic inflammatory indices in transgender persons at baseline and one year after starting GAHT.</p><p><strong>Method: </strong>A single center retrospective study including 50 assigned female at birth (AFAB) (median age 21.5 years) and 37 assigned male at birth (AMAB) persons (median age 29 years) with data separated by a 1-year period.</p><p><strong>Results: </strong>Testosterone therapy in AFAB persons led to a significant increase in VAT (P = 0.0006), trunk/limb ratio (P < 0.001), uric acid (P < 0.001), LDL-cholesterol (P < 0.05) and a significant decrease in HDL-cholesterol (P < 0.05). There were no changes in systemic inflammatory indices. Results of the final regression models indicated that increase in uric acid explained 33.2% of the variation in VAT [F(1,15) = 7.458; adjusted R square 0.332; P = 0.015]. In AMAB persons receiving GAHT, we observed an increase in total body fat (P = 0.002), fat mass index (P = 0.001) and HDL cholesterol (P < 0.05). The aspartate transaminase to lymphocyte ratio index decreased (P < 0.05) one year after the start of treatment.</p><p><strong>Conclusion: </strong>GAHT in the AFAB persons led to a significant increase in VAT and altered metabolic profile. There were no changes in systemic inflammatory indices. The AMAB people presented a non-deleterious cardiometabolic phenotype.</p><p><strong>Clinical trial registration: </strong>The study is registered at ClinicalTrials.gov (NCT04508231).</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"901-909"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chromogranin a and pancreatic polypeptide are not suitable for the screening of pancreatic neuroendocrine tumors in MEN1 - a long-term follow-up study.","authors":"Iiro Kostiainen, Susanna Majala, Jukka Schildt, Helka Parviainen, Saila Kauhanen, Niina Matikainen, Eeva M Ryhänen, Camilla Schalin-Jäntti","doi":"10.1007/s12020-025-04291-y","DOIUrl":"10.1007/s12020-025-04291-y","url":null,"abstract":"<p><strong>Purpose: </strong>In patients with multiple endocrine neoplasia type 1 (MEN1) followed up at ENETS centers of Excellence, chromogranin A (CgA) and pancreatic polypeptide (PP) are widely used screening tools for pancreatic neuroendocrine tumors (panNETs). Previous studies have demonstrated conflicting results regarding their performance in MEN1. This retrospective study aims to bring clarity to the question by investigating a well-characterized MEN1 cohort. We studied the impact of long-term biomarker follow-up on the clinical management of panNETs in MEN1.</p><p><strong>Methods: </strong>We calculated the sensitivity and specificity and performed ROC analysis of CgA and PP for diagnosing any panNET, ≥20 mm panNET, and metastatic panNET in comparison to imaging reference standard in 58 MEN1 patients. All patients had undergone somatostatin receptor PET/CT and conventional imaging. Longitudinal impact of 10-year annual biomarker measurements on real-life clinical management was analyzed from patient records.</p><p><strong>Results: </strong>Sensitivity of CgA (n = 48) and PP (n = 47) for diagnosing any panNET, ≥20 mm panNET, and metastatic panNET was 35%, 30%, and 60 and 23%, 33%, and 0%, respectively. For CgA, the AUC for diagnosing any panNET, ≥20 mm panNET, and metastatic panNET was 0.30 (95% CI 0.09-0.51), 0.49 (95% CI 0.29-0.68), and 0.69 (95% CI 0.42-0.95), respectively. For PP, the AUC for detection of metastatic panNET was 0.28 (95% CI 0.11-0.46). The annual biomarker measurements during 514 patient-years of follow-up did not affect the clinical management of panNETs.</p><p><strong>Conclusion: </strong>CgA and PP are not helpful in diagnosing panNETs in MEN1. It is time to revise the surveillance protocols in practice.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"910-920"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Searching for peripheral proteomic markers of primary aldosteronism.","authors":"Nikita Makhnov, Fredrik Axling, Elham Barazeghi, Peter Stålberg, Tobias Åkerström, Per Hellman","doi":"10.1007/s12020-025-04302-y","DOIUrl":"10.1007/s12020-025-04302-y","url":null,"abstract":"<p><strong>Purpose: </strong>Primary aldosteronism (PA) is prevalent among hypertensive patients, and associated with worsened cardiovascular outcomes compared to essential hypertension (HT). Screening and diagnostics for PA are currently complicated and invasive, why new methods are needed. Unilateral PA (uPA) is best treated surgically, and bilateral PA (bPA) - medically. No validated proteomic diagnostic test has been found yet. Our aim was to explore proteomic markers in peripheral serum to discriminate between HT, PA, uPA and bPA.</p><p><strong>Methods: </strong>Eighty-eight hypertensive individuals were evaluated for PA, and diagnosed with HT (n = 30); bPA (n = 29); and uPA (n = 29). Serum samples from these study groups were analyzed by Olink® Explore 384 Cardiometabolic Panel. A machine learning model based on ridge logistic regression with a stratified 5-fold cross-validation was used to identify HT, PA, bPA and uPA.</p><p><strong>Results: </strong>In the study groups, 56 circulating proteins were significantly different, and some of them specifically: 4 between PA vs. HT; 3 between bPA vs. uPA; 1 between bPA vs. HT; 9 between uPA vs. HT; 1 between HT vs. bPA vs. uPA. Three proteins with strongest differentiation (Coagulation factor IX for PA vs. HT; dipeptidyl peptidase 4 for uPA vs. HT and bPA; heat shock protein B1 for bPA vs. uPA) were validated by enzyme-linked immunosorbent assay. Our machine learning model could successfully identify 95% of HT, bPA, and uPA samples.</p><p><strong>Conclusion: </strong>Serum protein biomarkers may serve as a tool for discriminating HT, PA, uPA and bPA. Further studies are needed to support our results.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"869-878"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}